Volume 23, Number 9—September 2017
Cost of Nosocomial Outbreak Caused by NDM-1–Containing Klebsiella pneumoniae in the Netherlands, October 2015–January 2016
|Type of cost||Explanation||Total cost, US $||Total cost, €|
|Other laboratory personnel||Estimated 2,517 h†||93,789||76,251|
|Microbiological tests||Material costs to perform cultures in batches||60,070||48,837|
|Microbiologists||Estimated 376 h†||46,017||37,412|
|Molecular diagnostics||Material costs to perform PCRs in batches||24,523||19,937|
|No. blocked beds||582 beds, occupancy rate 0.85 at $550/d or €447/d (5)||272,085||221,131|
|Personal protective equipment||Expenditures for extra disposable aprons, gloves, and masks||55,121||44,814|
|Cleaning wards||Purchase of 2 fogging devices and personnel time for extra cleaning||46,881||38,115|
|Subtotal ward-related costs
|Other outbreak control costs|
|Infection prevention experts||Estimated 2,336 h for internal advice and guidance†||105,356||85,655|
|Patients in isolation||280 patients, averaged at 5.2 d of hospitalization, at $31.40/d or €25.53/d (6)||45,718||37,172|
|Staff meetings||23 staff meetings with on average 21 participants × 0.75 h × $1,525/h†||26,306||21,390|
|Communication||320 h for internal and patient-related communication spent by several communication employees†||17,696||14,387|
|Costs for mailings||10,701||8,700|
|Subtotal outbreak control costs
*Resource use related to this outbreak was provided by the hospital.
†Labor costs/h were determined by using the Dutch manual for economic evaluations (5).
- Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother. 2009;53:5046–54.
- Glasner C, Albiger B, Buist G, Tambić Andrasević A, Canton R, Carmeli Y, et al.; European Survey on Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) Working Group. Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Euro Surveill. 2013;18:20525.
- Giske CG, Monnet DL, Cars O, Carmeli Y; ReAct-Action on Antibiotic Resistance. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother. 2008;52:813–21.
- Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med. 2004;10(Suppl):S122–9.
- Zorginstituut Nederland. Guidance for carrying out economic evaluations in healthcare [in Dutch]. Amsterdam: Zorginstituut Nederland; 2015.
- Wassenberg MW, Kluytmans JA, Box AT, Bosboom RW, Buiting AG, van Elzakker EP, et al. Rapid screening of methicillin-resistant Staphylococcus aureus using PCR and chromogenic agar: a prospective study to evaluate costs and effects. Clin Microbiol Infect. 2010;16:1754–61.
- Ayraud-Thévenot S, Huart C, Mimoz O, Taouqi M, Laland C, Bousseau A, et al. Control of multi-drug-resistant Acinetobacter baumannii outbreaks in an intensive care unit: feasibility and economic impact of rapid unit closure. J Hosp Infect. 2012;82:290–2.
- Jiang Y, Resch S, Liu X, Rogers SO Jr, Askari R, Klompas M, et al. The cost of responding to an Acinetobacter outbreak in critically ill surgical patients. Surg Infect (Larchmt). 2016;17:58–64.
- Dik JW, Dinkelacker AG, Vemer P, Lo-Ten-Foe JR, Lokate M, Sinha B, et al. Cost-analysis of seven nosocomial outbreaks in an academic hospital. PLoS One. 2016;11:e0149226.
Page created: August 17, 2017
Page updated: August 17, 2017
Page reviewed: August 17, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.